
    
      The primary objective of this study is as follows:

        -  To evaluate the safety and tolerability of tenofovir following administration of
           tenofovir disoproxil fumarate 300 mg for 48 weeks in HIV-infected patients experiencing
           various degrees of renal impairment.

      The secondary objectives of this study are as follows:

        -  To evaluate the safety and tolerability of emtricitabine following administration of
           emtricitabine 200 mg for 48 weeks in HIV-infected patients experiencing various degrees
           of renal impairment.

        -  To evaluate the efficacy of tenofovir disoproxil fumarate in combination with
           emtricitabine in renally-impaired HIV-infected patients.

        -  To evaluate the pharmacokinetics of tenofovir and emtricitabine in renally-impaired
           HIV-infected patients.
    
  